Genetics of COPA syndrome
- PMID: 30804679
- PMCID: PMC6372856
- DOI: 10.2147/TACG.S153600
Genetics of COPA syndrome
Abstract
Inborn errors of immunity usually not only result in immunodeficiency but may also manifest as immune dysregulation in the form of autoinflammation, autoimmunity, or sometimes malignancy. One of the most recently discovered monogenic disorder of immune dysregulation is COPA syndrome. COPA syndrome is an inherited autoimmune disorder caused by mutations in COPA gene. COPA gene encodes for α subunit of the COP1 protein, which is involved in the reverse vesicular protein transport from Golgi apparatus to the endoplasmic reticulum (ER). The inheritance pattern of COPA syndrome is autosomal dominant, and the patients typically present with interstitial lung disease with pulmonary hemorrhage and subsequently develop arthritis. Immunological features involve autoantibody formation, elevated expression of IL-1β and IL-6, and increase in the number of Th17 cells. Molecular pathophysiology of COPA syndrome is not clearly understood. However, it is known that accumulation of unfolded proteins in ER leads to ER stress, which is an indirect result of aberrant vesicular transport of proteins from Golgi apparatus to ER and defective cellular autophagy. ER stress induces inflammation and is responsible for pathogenesis of a large number of chronic inflammatory diseases. Unfolded protein response process responds to improperly folded proteins and defends against stress in ER to ensure the fidelity of the protein folding. It maintains the expression of stress-response genes and causes initiation of inflammatory signaling pathways essential for the innate immunity. Mutation in COPA gene associated with defective protein sorting to ER has unearthed a new primary immunodeficiency disease with a unique clinical phenotype. This review highlights the clinical and molecular aspects of COPA syndrome.
Keywords: COPA syndrome; Golgi apparatus; arthritis; autoimmunity; autoinflammation; endoplasmic reticulum stress; interleukins; interstitial lung disease; protein transport.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures


Similar articles
-
Copa Syndrome: a Novel Autosomal Dominant Immune Dysregulatory Disease.J Clin Immunol. 2016 May;36(4):377-387. doi: 10.1007/s10875-016-0271-8. Epub 2016 Apr 5. J Clin Immunol. 2016. PMID: 27048656 Free PMC article. Review.
-
COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis.Nat Genet. 2015 Jun;47(6):654-60. doi: 10.1038/ng.3279. Epub 2015 Apr 20. Nat Genet. 2015. PMID: 25894502 Free PMC article.
-
STING-Mediated Lung Inflammation and Beyond.J Clin Immunol. 2021 Apr;41(3):501-514. doi: 10.1007/s10875-021-00974-z. Epub 2021 Feb 2. J Clin Immunol. 2021. PMID: 33532887 Review.
-
Heterozygous mutations in the C-terminal domain of COPA underlie a complex autoinflammatory syndrome.J Clin Invest. 2024 Jan 4;134(4):e163604. doi: 10.1172/JCI163604. J Clin Invest. 2024. PMID: 38175705 Free PMC article.
-
A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome.J Exp Med. 2020 Nov 2;217(11):e20201045. doi: 10.1084/jem.20201045. J Exp Med. 2020. PMID: 32725126 Free PMC article.
Cited by
-
Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.World J Pediatr. 2020 Feb;16(1):44-51. doi: 10.1007/s12519-019-00273-z. Epub 2019 Aug 3. World J Pediatr. 2020. PMID: 31377974 Review.
-
Integrated multiomics analysis identifies potential biomarkers and therapeutic targets for autophagy associated AKI to CKD transition.Sci Rep. 2025 Apr 21;15(1):13687. doi: 10.1038/s41598-025-97269-9. Sci Rep. 2025. PMID: 40258914 Free PMC article.
-
Establishment of a human induced pluripotent stem cell line (NIHTVBi031-A) derived from a COPA syndrome patient with a heterozygous p.Ala239Pro mutation.Stem Cell Res. 2024 Oct;80:103504. doi: 10.1016/j.scr.2024.103504. Epub 2024 Jul 19. Stem Cell Res. 2024. PMID: 39110999 Free PMC article.
-
Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know.Curr Rheumatol Rep. 2022 Jun;24(6):213-226. doi: 10.1007/s11926-022-01072-8. Epub 2022 Jun 1. Curr Rheumatol Rep. 2022. PMID: 35650373 Free PMC article. Review.
-
Emerging Treatments for Childhood Interstitial Lung Disease.Paediatr Drugs. 2024 Jan;26(1):19-30. doi: 10.1007/s40272-023-00603-9. Epub 2023 Nov 10. Paediatr Drugs. 2024. PMID: 37948041 Free PMC article.
References
-
- Sacri AS, Chambaraud T, Ranchin B, et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transplant. 2015;30(Suppl 1):104–112. - PubMed
-
- Siomou E, Tramma D, Bowen C, Milford DV. ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome. Pediatr Nephrol. 2012;27(10):1911–1920. - PubMed
-
- Morishita K, Li SC, Muscal E, et al. Assessing the performance of the birmingham vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe) J Rheumatol. 2012;39(5):1088–1094. - PubMed
Publication types
LinkOut - more resources
Full Text Sources